WO1993023569A1
(en)
*
|
1992-05-11 |
1993-11-25 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting viral replication
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040219569A1
(en)
*
|
1999-07-06 |
2004-11-04 |
Fruma Yehiely |
Gene identification method
|
US20110003879A1
(en)
*
|
2005-03-11 |
2011-01-06 |
Vincent Mark D |
Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
NZ547283A
(en)
|
1998-03-20 |
2008-06-30 |
Commw Scient Ind Res Org |
Control of gene expression
|
EP1071753A2
(en)
*
|
1998-04-20 |
2001-01-31 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
EP1147204A1
(en)
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
US6656698B1
(en)
*
|
1999-06-30 |
2003-12-02 |
Millennium Pharmaceuticals, Inc. |
12832, a novel human kinase-like molecule and uses thereof
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
US8128922B2
(en)
|
1999-10-20 |
2012-03-06 |
Johns Hopkins University |
Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7179796B2
(en)
*
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
WO2002081628A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
JP2003526367A
(ja)
*
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
PT2361981E
(pt)
*
|
2000-03-30 |
2013-06-12 |
Max Planck Gesellschaft |
Mediadores de interferência por rna específicos de sequência de rna
|
AU2001249622B2
(en)
*
|
2000-03-30 |
2007-06-07 |
Massachusetts Institute Of Technology |
RNA sequence-specific mediators of RNA interference
|
US20080242627A1
(en)
*
|
2000-08-02 |
2008-10-02 |
University Of Southern California |
Novel rna interference methods using dna-rna duplex constructs
|
US7662791B2
(en)
*
|
2000-08-02 |
2010-02-16 |
University Of Southern California |
Gene silencing using mRNA-cDNA hybrids
|
JP5087201B2
(ja)
*
|
2000-08-03 |
2012-12-05 |
ジョンズ・ホプキンス・ユニバーシティ |
抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US7691821B2
(en)
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
US20020165192A1
(en)
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
WO2002044321A2
(en)
|
2000-12-01 |
2002-06-06 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference mediating small rna molecules
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
EP1229134A3
(en)
*
|
2001-01-31 |
2004-01-28 |
Nucleonics, Inc |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
WO2003070897A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
WO2002097114A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050176663A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
WO2003070743A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
WO2003070983A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
WO2005014811A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050176024A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124569A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US20050239731A1
(en)
*
|
2001-05-18 |
2005-10-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050048529A1
(en)
*
|
2002-02-20 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
CA2526831C
(en)
*
|
2001-05-18 |
2012-07-31 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
WO2003070197A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050196781A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20060148743A1
(en)
*
|
2001-05-18 |
2006-07-06 |
Vasant Jadhav |
RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
DE10133858A1
(de)
*
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
WO2003006477A1
(en)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
US10590418B2
(en)
*
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
JP2005508306A
(ja)
|
2001-07-23 |
2005-03-31 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
哺乳類における遺伝子発現のRNAiによる阻害に関する方法および組成物
|
US20090247606A1
(en)
*
|
2001-08-28 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
US20040248835A1
(en)
*
|
2001-10-26 |
2004-12-09 |
Anja Krebs |
Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
|
WO2003035870A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung eines pankreaskarzinoms
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
WO2003035083A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
IL161733A0
(en)
*
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
WO2003044188A1
(fr)
*
|
2001-11-21 |
2003-05-30 |
Mitsubishi Chemical Corporation |
Procede pour inhiber l'expression de genes
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US7294504B1
(en)
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
HU229452B1
(en)
*
|
2002-01-17 |
2013-12-30 |
Univ British Columbia |
Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
GB0201477D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Forschungsstiftung |
Methods of obtaining isoform specific expression in mammalian cells
|
US20040014956A1
(en)
|
2002-02-01 |
2004-01-22 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
EP1572902B1
(en)
*
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
AU2003223172A1
(en)
*
|
2002-02-12 |
2003-09-04 |
Quark Biotech, Inc. |
Use of the axl receptor for diagnosis and treatment of renal disease
|
EP1474512A2
(en)
*
|
2002-02-13 |
2004-11-10 |
Axordia Limited |
Method to modify differentiation of pluripotential stem cells
|
JP2005527198A
(ja)
*
|
2002-02-14 |
2005-09-15 |
シティ・オブ・ホープ |
哺乳動物細胞において、干渉rna分子を産生する方法、および該干渉rna分子の療法的使用
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090247613A1
(en)
*
|
2002-02-20 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7662952B2
(en)
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
EP1501853A4
(en)
*
|
2002-02-20 |
2005-11-16 |
Sirna Therapeutics Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR USING SHORT INTERFERING NUCLEIC ACIDS
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
WO2003070966A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7893248B2
(en)
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
*
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US20090253773A1
(en)
*
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20090306182A1
(en)
*
|
2002-02-20 |
2009-12-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US8232383B2
(en)
*
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20090137509A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
GB2397062B
(en)
*
|
2002-02-20 |
2005-06-15 |
Sirna Therapeutics Inc |
RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20090093439A1
(en)
*
|
2002-02-20 |
2009-04-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US20090233983A1
(en)
*
|
2002-02-20 |
2009-09-17 |
Sirna Therapeutics Inc. |
RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA
|
US7928218B2
(en)
*
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20100240730A1
(en)
*
|
2002-02-20 |
2010-09-23 |
Merck Sharp And Dohme Corp. |
RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
|
WO2003072745A2
(en)
*
|
2002-02-22 |
2003-09-04 |
Eshleman James R |
Antigene locks and therapeutic uses thereof
|
EP2277522B1
(en)
*
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Methods for increasing or decreasing bone density and identifying molecules
|
EP1572923A4
(en)
*
|
2002-03-06 |
2007-10-31 |
Rigel Pharmaceuticals Inc |
NEW METHOD FOR THE INTRODUCTION AND INTRA-CELLULAR SYNTHESIS OF SIRNA MOLECULES
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
JP2005521393A
(ja)
*
|
2002-03-20 |
2005-07-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
Hiv治療
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
US20050222061A1
(en)
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
ES2465574T3
(es)
|
2002-05-03 |
2014-06-06 |
Duke University |
Un método para regular la expresión génica
|
US7199107B2
(en)
*
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
AU2003283951A1
(en)
|
2002-05-23 |
2004-03-03 |
Ceptyr, Inc. |
Modulation of biological signal transduction by rna interference
|
AU2003237686A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Rna interference mediating small rna molecules
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
AU2003243541A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Ambion, Inc. |
Methods and compositions relating to labeled rna molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
EP1513538A4
(en)
*
|
2002-06-14 |
2007-08-22 |
Mirus Bio Corp |
Novel methods for introducing polynucleotides into cells
|
CN1662652B
(zh)
*
|
2002-06-21 |
2011-05-25 |
北京诺赛基因组研究中心有限公司 |
随机化的dna文库和双链rna文库,其用途及生产方法
|
CA2491034A1
(en)
*
|
2002-06-26 |
2004-01-08 |
The Penn State Research Foundation |
Methods and materials for treating human papillomavirus infections
|
CA2491164C
(en)
|
2002-06-28 |
2012-05-08 |
Cory Giesbrecht |
Method and apparatus for producing liposomes
|
EP1520022B1
(en)
*
|
2002-07-10 |
2015-07-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna-interference by single-stranded rna molecules
|
US7148342B2
(en)
*
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
TR201708347T4
(tr)
*
|
2002-08-05 |
2019-02-21 |
Silence Therapeutics Gmbh |
Müdahaleci rna moleküllerinin diğer yeni biçimleri.
|
DK1389637T3
(da)
|
2002-08-05 |
2012-09-03 |
Silence Therapeutics Ag |
Interfererende RNA-molekyler med stumpe ender
|
AU2012216354B2
(en)
*
|
2002-08-05 |
2016-01-14 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
AU2015264957B2
(en)
*
|
2002-08-05 |
2017-10-26 |
Silence Therapeutics Gmbh |
Further novel forms of interfering rna molecules
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
EP1527176B2
(en)
|
2002-08-05 |
2017-03-22 |
Silence Therapeutics GmbH |
Further novel forms of interfering rna molecules
|
CN100345593C
(zh)
*
|
2002-08-06 |
2007-10-31 |
东丽株式会社 |
用于制备肾脏疾病的治疗或预防药物中的用途
|
US20060211637A1
(en)
*
|
2002-08-06 |
2006-09-21 |
Intradigm Corporation |
Methods of down regulating target gene expression in vivo by introduction of interfering rna
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
DE60325740D1
(de)
|
2002-08-14 |
2009-02-26 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
KR101117673B1
(ko)
*
|
2002-08-21 |
2012-03-07 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
|
US7956176B2
(en)
*
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US20060287269A1
(en)
*
|
2002-09-09 |
2006-12-21 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20040138119A1
(en)
*
|
2002-09-18 |
2004-07-15 |
Ingo Tamm |
Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis
|
US20060257380A1
(en)
*
|
2002-09-19 |
2006-11-16 |
Inst.Nat. De La Sante Et De La Recherche MED |
Use of sirnas for gene silencing in antigen presenting cells
|
AU2003282877B9
(en)
*
|
2002-09-25 |
2011-05-12 |
University Of Massachusetts |
In Vivo gene silencing by chemically modified and stable siRNA
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
AU2003279010A1
(en)
*
|
2002-09-28 |
2004-04-19 |
Massachusetts Institute Of Technology |
Compositions and methods for delivery of short interfering rna and short hairpin rna
|
US20060240425A1
(en)
*
|
2002-09-30 |
2006-10-26 |
Oncotherapy Science, Inc |
Genes and polypeptides relating to myeloid leukemia
|
US7422853B1
(en)
*
|
2002-10-04 |
2008-09-09 |
Myriad Genetics, Inc. |
RNA interference using a universal target
|
US7521431B2
(en)
*
|
2002-11-01 |
2009-04-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
AU2003287502B2
(en)
|
2002-11-05 |
2010-12-09 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003287464A1
(en)
*
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
2'-fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
DE10322662A1
(de)
*
|
2002-11-06 |
2004-10-07 |
Grünenthal GmbH |
Wirksame und stabile DNA-Enzyme
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20090005548A1
(en)
*
|
2002-11-14 |
2009-01-01 |
Dharmacon, Inc. |
siRNA targeting nuclear receptor interacting protein 1 (NRIP1)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US10920226B2
(en)
*
|
2002-11-14 |
2021-02-16 |
Thermo Fisher Scientific Inc. |
siRNA targeting LDHA
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
DK2284266T3
(da)
*
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
CA2506619A1
(en)
|
2002-11-18 |
2004-08-19 |
Thomas W. Hodge |
Cell lines and host nucleic acid sequences related to infectious disease
|
US7064337B2
(en)
|
2002-11-19 |
2006-06-20 |
The Regents Of The University Of California |
Radiation detection system for portable gamma-ray spectroscopy
|
DE10254214A1
(de)
*
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
EP2298886A3
(en)
*
|
2002-11-22 |
2011-12-14 |
Bio-Think Tank Co., Ltd. |
Method for searching target base sequence of RNA interference, method for designing base sequence of polynucleotide for causing RNA interference, method for producing double-stranded polynucleotide, method for inhibiting gene expression, base sequence processing apparatus, program for running base sequence processing method on computer, recording medium, and base sequence processing system
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
AU2003298718A1
(en)
*
|
2002-11-22 |
2004-06-18 |
University Of Massachusetts |
Modulation of hiv replication by rna interference
|
US7829694B2
(en)
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7618948B2
(en)
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
US20130130231A1
(en)
|
2002-11-26 |
2013-05-23 |
Isaac Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7696334B1
(en)
|
2002-12-05 |
2010-04-13 |
Rosetta Genomics, Ltd. |
Bioinformatically detectable human herpesvirus 5 regulatory gene
|
WO2004048545A2
(en)
*
|
2002-11-26 |
2004-06-10 |
University Of Massachusetts |
DELIVERY OF siRNAs______________________________________________
|
CN1301263C
(zh)
|
2002-12-18 |
2007-02-21 |
北京昭衍新药研究中心 |
一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
|
WO2004058184A2
(en)
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2512337A1
(en)
*
|
2003-01-03 |
2004-07-29 |
Gencia Corporation |
Sirna mediated post-transcriptional gene silencing of genes involved in alopecia
|
ATE477337T1
(de)
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
|
US7629323B2
(en)
*
|
2003-01-21 |
2009-12-08 |
Northwestern University |
Manipulation of neuronal ion channels
|
US20040147027A1
(en)
*
|
2003-01-28 |
2004-07-29 |
Troy Carol M. |
Complex for facilitating delivery of dsRNA into a cell and uses thereof
|
US20060178297A1
(en)
*
|
2003-01-28 |
2006-08-10 |
Troy Carol M |
Systems and methods for silencing expression of a gene in a cell and uses thereof
|
US7732591B2
(en)
|
2003-11-25 |
2010-06-08 |
Medtronic, Inc. |
Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
AU2004211949A1
(en)
*
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
RNAi targeting of viruses
|
FR2850971B1
(fr)
*
|
2003-02-10 |
2006-08-11 |
Aventis Pharma Sa |
Oligonucleotide antisens inhibant l'expression de la proteine ob-rgrp et procede de detection de composes modifiant l'interaction entre la famille de la proteine ob-rgrp et le recepteur de la leptine
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20040162235A1
(en)
*
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
EP1594441B1
(en)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
|
US8796235B2
(en)
*
|
2003-02-21 |
2014-08-05 |
University Of South Florida |
Methods for attenuating dengue virus infection
|
AU2004265550A1
(en)
*
|
2003-02-21 |
2005-02-24 |
The Penn State Research Foundation |
RNA interference compositions and methods
|
CN1780913A
(zh)
*
|
2003-02-27 |
2006-05-31 |
独立行政法人产业技术总合研究所 |
哺乳动物细胞中dsRNA诱导CpG序列甲基化
|
WO2004076629A2
(en)
|
2003-02-27 |
2004-09-10 |
Nucleonics Inc. |
METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
|
TW200427695A
(en)
*
|
2003-03-05 |
2004-12-16 |
Senesco Technologies Inc |
Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
|
US20050164212A1
(en)
*
|
2003-03-06 |
2005-07-28 |
Todd Hauser |
Modulation of gene expression using DNA-RNA hybrids
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
US7862816B2
(en)
*
|
2003-03-12 |
2011-01-04 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
DE602004023279D1
(de)
|
2003-03-21 |
2009-11-05 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
ATE536408T1
(de)
*
|
2003-04-02 |
2011-12-15 |
Dharmacon Inc |
Modifizierte polynukleotide zur verwendung bei rna-interferenz
|
WO2004090105A2
(en)
*
|
2003-04-02 |
2004-10-21 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
EP1631669A2
(en)
|
2003-04-09 |
2006-03-08 |
Biodelivery Sciences International, Inc. |
Cochleate compositions directed against expression of proteins
|
AU2004229519B2
(en)
|
2003-04-09 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
iRNA conjugates
|
WO2004092383A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
EP1625138A4
(en)
|
2003-04-17 |
2010-06-23 |
Alnylam Pharmaceuticals Inc |
PROTECTED MONOMERS
|
JP4597976B2
(ja)
|
2003-04-17 |
2010-12-15 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
修飾iRNA剤
|
JP2006523464A
(ja)
*
|
2003-04-18 |
2006-10-19 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
アンジオポエチン1、2、及びそれらの受容体TIE2のsiRNA阻害のための組成物及びその方法
|
US20070010468A1
(en)
*
|
2003-04-23 |
2007-01-11 |
Georgetown University |
Methods and compositions for the inhibition of stat5 in prostate cancer cells
|
US9701725B2
(en)
*
|
2003-05-05 |
2017-07-11 |
The Johns Hopkins University |
Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
|
JP2007502129A
(ja)
|
2003-05-09 |
2007-02-08 |
ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション |
短鎖干渉rnaライブラリーならびに合成および使用の方法
|
ATE516047T1
(de)
|
2003-05-09 |
2011-07-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und anwendungsverfahren
|
CN1780920B
(zh)
*
|
2003-05-12 |
2012-03-28 |
波多玛克制药有限公司 |
基因表达抑制剂
|
WO2004104199A2
(en)
*
|
2003-05-15 |
2004-12-02 |
Oligo Engine, Inc. |
Modulation of gene expression using dna-dna hybrids
|
CA2525619A1
(en)
*
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
EP1625853B1
(en)
|
2003-05-19 |
2015-07-08 |
Genecare Research Institute Co., Ltd |
Apoptosis inducer for cancer cell
|
US20080020990A1
(en)
*
|
2003-05-30 |
2008-01-24 |
Nippon Shinyaku Co., Ltd. |
Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same
|
WO2004105774A1
(ja)
*
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
|
EP3502252B1
(en)
|
2003-06-02 |
2023-04-05 |
University of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
ATE485394T1
(de)
*
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
US20050019918A1
(en)
*
|
2003-06-03 |
2005-01-27 |
Hidetoshi Sumimoto |
Treatment of cancer by inhibiting BRAF expression
|
US7595306B2
(en)
*
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
US8575327B2
(en)
|
2003-06-12 |
2013-11-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
EP1486564A1
(de)
*
|
2003-06-13 |
2004-12-15 |
Ribopharma AG |
SiRNA mit erhöhter Stabilität in Serum
|
AU2004263830B2
(en)
|
2003-06-13 |
2008-12-18 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
US7790691B2
(en)
*
|
2003-06-20 |
2010-09-07 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
|
EP1636342A4
(en)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
OLIGOMERIC COMPOUNDS FOR GENE MODULATION
|
EP1692153A4
(en)
*
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
EP1649019A2
(en)
*
|
2003-07-15 |
2006-04-26 |
California Institute Of Technology |
Improved inhibitor nucleic acids
|
US20050256071A1
(en)
*
|
2003-07-15 |
2005-11-17 |
California Institute Of Technology |
Inhibitor nucleic acids
|
JP4951338B2
(ja)
*
|
2003-07-16 |
2012-06-13 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質に封入された干渉rna
|
WO2005010188A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Whitehead Institute For Biomedical Research |
Rnas able to modulate chromatin silencing
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
AU2004267425B2
(en)
*
|
2003-08-13 |
2010-10-21 |
The Board Of Trustees Of The University Of Illinois |
Silencing of TGF-beta receptor type II expression by sIRNA
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7825235B2
(en)
*
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
WO2005035759A2
(en)
*
|
2003-08-20 |
2005-04-21 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
AU2004269150C1
(en)
|
2003-08-28 |
2010-11-18 |
Novartis Ag |
Interfering RNA duplex having blunt-ends and 3'-modifications
|
US8501705B2
(en)
*
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
US7947658B2
(en)
*
|
2003-09-12 |
2011-05-24 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
US8680063B2
(en)
*
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
EP2256200A3
(en)
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E expression
|
JP2007505634A
(ja)
*
|
2003-09-22 |
2007-03-15 |
ロゼッタ インファーマティクス エルエルシー |
Rna干渉を用いる合成致死スクリーニング
|
WO2005033310A1
(de)
*
|
2003-10-01 |
2005-04-14 |
Grünenthal GmbH |
Pim-1-spezifische dsrna-verbindungen
|
JP2007517498A
(ja)
*
|
2003-10-07 |
2007-07-05 |
アステラス製薬株式会社 |
骨形態形成タンパク質(bmp)2a及びその使用
|
EP1711613B1
(en)
|
2003-10-09 |
2013-04-10 |
E.I. Du Pont De Nemours And Company |
Gene silencing by using micro-rna molecules
|
WO2005045032A2
(en)
*
|
2003-10-20 |
2005-05-19 |
Sima Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2005045038A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA)
|
WO2005044981A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US7962316B2
(en)
|
2003-10-27 |
2011-06-14 |
Merck Sharp & Dohme Corp. |
Method of designing siRNAs for gene silencing
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
US20070258993A1
(en)
*
|
2003-11-12 |
2007-11-08 |
The Austin Research Institute |
Dna-Carrier Conjugate
|
US7763592B1
(en)
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
JP2005168485A
(ja)
*
|
2003-11-20 |
2005-06-30 |
Tsutomu Suzuki |
siRNAの設計方法
|
US7807646B1
(en)
*
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US20050208658A1
(en)
*
|
2003-11-21 |
2005-09-22 |
The University Of Maryland |
RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
|
US20100145038A1
(en)
*
|
2003-11-24 |
2010-06-10 |
Merck & Co., Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2004294567A1
(en)
|
2003-11-26 |
2005-06-16 |
University Of Massachusetts |
Sequence-specific inhibition of small RNA function
|
US20080171051A1
(en)
*
|
2003-11-26 |
2008-07-17 |
Patrick Gerard Johnston |
Cancer Treatment
|
WO2005056021A1
(en)
|
2003-12-04 |
2005-06-23 |
University Of South Florida |
Polynucleotides for reducing respiratory syncytial virus gene expression
|
JP2007513968A
(ja)
*
|
2003-12-12 |
2007-05-31 |
ウイスコンシン アラムニ リサーチ ファンデーション |
哺乳動物神経細胞へのsiRNAのデリバリー
|
WO2005068630A1
(ja)
*
|
2003-12-16 |
2005-07-28 |
National Institute Of Advanced Industrial Science And Technology |
干渉用二重鎖rna
|
US20060134787A1
(en)
*
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
MXPA06007269A
(es)
*
|
2003-12-23 |
2007-07-09 |
Univ Pennsylvania |
Composiciones y metodos para terapia combinada de enfermedad.
|
EP1726313A4
(en)
*
|
2004-01-16 |
2008-04-09 |
Takeda Pharmaceutical |
MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS
|
US20080249039A1
(en)
*
|
2004-01-30 |
2008-10-09 |
Santaris Pharma A/S |
Modified Short Interfering Rna (Modified Sirna)
|
JP4755113B2
(ja)
*
|
2004-01-30 |
2011-08-24 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
|
US20070269889A1
(en)
*
|
2004-02-06 |
2007-11-22 |
Dharmacon, Inc. |
Stabilized siRNAs as transfection controls and silencing reagents
|
US7858769B2
(en)
|
2004-02-10 |
2010-12-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US20050273868A1
(en)
*
|
2004-02-17 |
2005-12-08 |
University Of Massachusetts |
Methods and compositions for enhancing RISC activity in vitro and in vivo
|
US20060069050A1
(en)
*
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
EP1566202A1
(en)
*
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Use of resistin antagonists in the treatment of rheumatoid arthritis
|
EP1718367A1
(en)
*
|
2004-02-23 |
2006-11-08 |
Genzyme Corporation |
Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
|
CA2557426A1
(en)
|
2004-02-24 |
2005-10-06 |
Thomas W. Hodge |
Rab9a, rab11a, and modulators thereof related to infectious disease
|
US7691823B2
(en)
*
|
2004-03-05 |
2010-04-06 |
University Of Massachusetts |
RIP140 regulation of glucose transport
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005089224A2
(en)
|
2004-03-12 |
2005-09-29 |
Alnylam Pharmaceuticals, Inc. |
iRNA AGENTS TARGETING VEGF
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
AU2005222965B8
(en)
*
|
2004-03-15 |
2010-07-01 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20050208090A1
(en)
*
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
US7851452B2
(en)
*
|
2004-03-22 |
2010-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods of use of bcl-6-derived nucleotides to induce apoptosis
|
US20050272682A1
(en)
*
|
2004-03-22 |
2005-12-08 |
Evers Bernard M |
SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy
|
DK1730280T3
(en)
*
|
2004-03-26 |
2019-02-04 |
Curis Inc |
RNA interference modulators for hedgehog signaling and applications thereof
|
WO2005095622A2
(en)
*
|
2004-03-26 |
2005-10-13 |
Van Andel Research Institute |
c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY
|
JP2005312428A
(ja)
*
|
2004-03-31 |
2005-11-10 |
Keio Gijuku |
Skp−2発現抑制を利用した癌の治療
|
WO2005095647A1
(ja)
*
|
2004-03-31 |
2005-10-13 |
Takara Bio Inc. |
siRNAのスクリーニング方法
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
CA2561741C
(en)
*
|
2004-04-05 |
2016-09-27 |
Alnylam Pharmaceuticals, Inc. |
Processes and reagents for oligonucleotide synthesis and purification
|
EP2520652B1
(en)
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
|
US20060078902A1
(en)
*
|
2004-04-15 |
2006-04-13 |
Michaeline Bunting |
Method and compositions for RNA interference
|
CA2564616C
(en)
*
|
2004-04-20 |
2016-08-30 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
WO2005105157A2
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Ofnew York |
INHIBITION OF HAIRLESS PROTEIN mRNA
|
US7626014B2
(en)
|
2004-04-27 |
2009-12-01 |
Alnylam Pharmaceuticals |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
WO2005115405A1
(en)
|
2004-04-28 |
2005-12-08 |
Molecules For Health, Inc. |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
EP1750776A2
(en)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a c5-modified pyrimidine
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US20050260214A1
(en)
*
|
2004-05-12 |
2005-11-24 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
US20110117088A1
(en)
*
|
2004-05-12 |
2011-05-19 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
WO2005110464A2
(en)
*
|
2004-05-14 |
2005-11-24 |
Oregon Health & Science University |
Irx5 inhibition as treatment for hyperproliferative disorders
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
AU2005243410B2
(en)
|
2004-05-14 |
2010-04-22 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
CA2567741A1
(en)
*
|
2004-05-25 |
2006-03-30 |
Chimeracore, Inc. |
Self-assembling nanoparticle drug delivery system
|
US7795419B2
(en)
*
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
JP5435864B2
(ja)
|
2004-05-28 |
2014-03-05 |
アシュラジェン インコーポレイテッド |
マイクロrnaに関与する方法および組成物
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
CA2569664C
(en)
*
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
JP4764426B2
(ja)
*
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
US20060008907A1
(en)
*
|
2004-06-09 |
2006-01-12 |
The Curators Of The University Of Missouri |
Control of gene expression via light activated RNA interference
|
WO2006085942A2
(en)
*
|
2004-06-17 |
2006-08-17 |
The Regents Of The University Of California |
Compositions and methods for regulating gene transcription
|
US20060051815A1
(en)
*
|
2004-06-25 |
2006-03-09 |
The J. David Gladstone Institutes |
Methods of treating smooth muscle cell disorders
|
JP2008504840A
(ja)
|
2004-06-30 |
2008-02-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
非リン酸骨格結合を含むオリゴヌクレオチド
|
CA2572439A1
(en)
*
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
US8143228B2
(en)
*
|
2004-07-12 |
2012-03-27 |
Medical Research Fund Of Tel Aviv Sourasky Medical Center |
Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
|
JP2008522951A
(ja)
*
|
2004-07-19 |
2008-07-03 |
ベイラー・カレツジ・オブ・メデイシン |
サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
|
US7579451B2
(en)
|
2004-07-21 |
2009-08-25 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
US7767652B2
(en)
*
|
2004-07-21 |
2010-08-03 |
Medtronic, Inc. |
Medical devices and methods for reducing localized fibrosis
|
US20060030538A1
(en)
*
|
2004-07-21 |
2006-02-09 |
Medtronic, Inc. |
Methods for reducing or preventing localized fibrosis using SiRNA
|
US20100132058A1
(en)
|
2004-07-23 |
2010-05-27 |
Diatchenko Luda B |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
CA2574603C
(en)
|
2004-08-04 |
2014-11-04 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
JP5192234B2
(ja)
|
2004-08-10 |
2013-05-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
化学修飾オリゴヌクレオチド
|
WO2006020557A2
(en)
*
|
2004-08-10 |
2006-02-23 |
Immusol, Inc. |
Methods of using or identifying agents that inhibit cancer growth
|
US20060063181A1
(en)
*
|
2004-08-13 |
2006-03-23 |
Green Pamela J |
Method for identification and quantification of short or small RNA molecules
|
CN101123994B
(zh)
|
2004-08-16 |
2012-11-14 |
夸克医药公司 |
Rtp801的抑制剂的治疗性用途
|
US20070021366A1
(en)
*
|
2004-11-19 |
2007-01-25 |
Srivastava Satish K |
Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
|
PT1781787T
(pt)
|
2004-08-23 |
2017-07-17 |
Sylentis Sau |
Tratamento de distúrbios oculares caracterizados por uma pressão intraocular elevada por meio de arnsis
|
US7323310B2
(en)
|
2004-08-31 |
2008-01-29 |
Qiagen North American Holdings, Inc. |
Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase
|
CA2594672C
(en)
*
|
2004-08-31 |
2014-12-30 |
Ana I. Jimenez |
Methods and compositions to inhibit p2x7 receptor expression
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
WO2006033965A2
(en)
*
|
2004-09-16 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
NZ572403A
(en)
*
|
2004-09-24 |
2010-03-26 |
Alnylam Pharmaceuticals Inc |
Rnai modulation of apob and uses thereof
|
CN102643818B
(zh)
|
2004-09-28 |
2014-04-09 |
夸克制药公司 |
寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
|
EP1796686A4
(en)
*
|
2004-09-30 |
2008-05-14 |
Centocor Inc |
EMMPRINE ANTAGONISTS AND ITS USES
|
CA2584960A1
(en)
*
|
2004-10-21 |
2006-05-04 |
Charles L. Niblett |
Methods and materials for conferring resistance to pests and pathogens of plants
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
CN101084309A
(zh)
*
|
2004-10-22 |
2007-12-05 |
诺伊热尼有限公司 |
神经元再生
|
US7592322B2
(en)
*
|
2004-10-22 |
2009-09-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US20060110440A1
(en)
*
|
2004-10-22 |
2006-05-25 |
Kiminobu Sugaya |
Method and system for biasing cellular development
|
AU2005299296A1
(en)
|
2004-10-27 |
2006-05-04 |
Vanderbilt University |
Mammalian genes involved in infection
|
EP2371954A1
(en)
*
|
2004-10-27 |
2011-10-05 |
Schering Corporation |
Compositions and methods for short interfering nucleic acid inhibition of NAv1.8
|
CN101048139A
(zh)
*
|
2004-10-28 |
2007-10-03 |
艾德克斯实验室公司 |
药物活性化合物的控释组合物
|
US20060094676A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Ronit Lahav |
Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
DK2302055T3
(da)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
|
US8809287B2
(en)
*
|
2004-11-15 |
2014-08-19 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for altering Wnt autocrine signaling
|
US20060105052A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Acar Havva Y |
Cationic nanoparticle having an inorganic core
|
EP2199298A1
(en)
*
|
2004-11-17 |
2010-06-23 |
Protiva Biotherapeutics Inc. |
Sirna silencing of Apolipoprotein B
|
AU2005307737C1
(en)
*
|
2004-11-18 |
2013-08-29 |
The Board Of Trustees Of The University Of Illinois |
Multicistronic siRNA constructs to inhibit tumors
|
US8314073B2
(en)
*
|
2004-11-19 |
2012-11-20 |
Genecare Research Institute Co., Ltd. |
Cancer-cell-specific cell proliferation inhibitors
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
EP1814597A4
(en)
*
|
2004-11-24 |
2009-04-22 |
Alnylam Pharmaceuticals Inc |
RNAI MODULATION OF BCR-ABL FUSION GENE AND APPLICATIONS THEREOF
|
JP2008521909A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ビー−ブリッジ インターナショナル,インコーポレーテッド |
短鎖干渉rna、アンチセンスポリヌクレオチド、および他のハイブリッド形成化ポリヌクレオチドの設計方法
|
US20060165667A1
(en)
*
|
2004-12-03 |
2006-07-27 |
Case Western Reserve University |
Novel methods, compositions and devices for inducing neovascularization
|
EP1824872B1
(en)
*
|
2004-12-14 |
2012-02-08 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of mll-af4 and uses thereof
|
WO2006066048A2
(en)
|
2004-12-17 |
2006-06-22 |
Beth Israel Deaconess Medical Center |
Compositions for bacterial mediated gene silencing and methods of using same
|
GB0427916D0
(en)
*
|
2004-12-21 |
2005-01-19 |
Astrazeneca Ab |
Method
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
BRPI0519468A2
(pt)
|
2004-12-27 |
2009-01-27 |
Silence Therapeutics Ag |
complexos de lipÍdeos revestido e seu uso
|
MX2007008065A
(es)
*
|
2004-12-30 |
2008-03-04 |
Todd M Hauser |
Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
|
CA2594040A1
(en)
*
|
2005-01-06 |
2006-07-13 |
The Johns Hopkins University |
Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
|
DK1841793T3
(da)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
US7507809B2
(en)
*
|
2005-01-07 |
2009-03-24 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV and therapeutic uses thereof
|
EP1841464B1
(en)
*
|
2005-01-24 |
2012-06-27 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of the nogo-l or nogo-r gene and uses thereof
|
CA2595726A1
(en)
*
|
2005-01-26 |
2006-08-03 |
The Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
|
TW200639253A
(en)
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular targets
|
EP1848805A2
(en)
*
|
2005-02-14 |
2007-10-31 |
HVC Strategic Research Institute, Inc |
Pharmaceutical agents for preventing metastasis of cancer
|
NZ595305A
(en)
|
2005-02-14 |
2013-06-28 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
WO2006102970A2
(en)
*
|
2005-03-08 |
2006-10-05 |
Qiagen Gmbh |
Modified short interfering rna
|
JP2008533050A
(ja)
|
2005-03-11 |
2008-08-21 |
アルコン,インコーポレイテッド |
緑内障を処置するためのフリッツルド関連蛋白質―1のrnai媒介性阻害
|
GB0505081D0
(en)
*
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
US8999943B2
(en)
*
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
JP4585342B2
(ja)
*
|
2005-03-18 |
2010-11-24 |
株式会社資生堂 |
不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法
|
ATE524546T1
(de)
*
|
2005-03-25 |
2011-09-15 |
Medtronic Inc |
Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
|
AU2006230436B2
(en)
*
|
2005-03-31 |
2011-11-24 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
US20060257912A1
(en)
|
2005-05-06 |
2006-11-16 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
WO2006130560A2
(en)
*
|
2005-05-31 |
2006-12-07 |
The Trustees Of The University Of Pennsylvania |
Manipulation of pten in t cells as a strategy to modulate immune responses
|
US9505867B2
(en)
*
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8802640B2
(en)
*
|
2005-06-01 |
2014-08-12 |
Polyplus-Transfection Sa |
Oligonucleotides for RNA interference and biological applications thereof
|
EP1885739A4
(en)
*
|
2005-06-01 |
2010-02-10 |
Univ Duke |
METHOD FOR INHIBITING INTERNAL HYPERPLASIA
|
WO2006131925A2
(en)
*
|
2005-06-10 |
2006-12-14 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
CN100445381C
(zh)
*
|
2005-06-10 |
2008-12-24 |
中国人民解放军军事医学科学院基础医学研究所 |
带有单链polyA尾巴的siRNA分子制备方法和应用
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7838503B2
(en)
*
|
2005-06-15 |
2010-11-23 |
Children's Medical Center Corporation |
Methods for extending the replicative lifespan of cells
|
FI20050640A0
(fi)
*
|
2005-06-16 |
2005-06-16 |
Faron Pharmaceuticals Oy |
Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
|
CN101501055B
(zh)
*
|
2005-06-23 |
2016-05-11 |
贝勒医学院 |
负性免疫调节因子的调节和免疫疗法应用
|
CA2608964A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and therapeutic uses thereof
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
JP5383186B2
(ja)
*
|
2005-07-07 |
2014-01-08 |
イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド |
H19をダウンレギュレートする核酸薬剤、及びそれを使用する方法
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
JP5383189B2
(ja)
*
|
2005-07-25 |
2014-01-08 |
リボックス・ゲーエムベーハー |
Rna依存性rnaポリメラーゼ、rnaを増幅するため及び/又は標識するための方法並びにキット
|
US20070111227A1
(en)
*
|
2005-07-28 |
2007-05-17 |
Green Pamela J |
Small regulatory RNAs and methods of use
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
US20070213257A1
(en)
*
|
2005-08-12 |
2007-09-13 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for complexes of nucleic acids and peptides
|
CA2619534A1
(en)
*
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
US20090018097A1
(en)
*
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
WO2007033058A2
(en)
*
|
2005-09-13 |
2007-03-22 |
Trustees Of Dartmouth College |
Compositions and methods for regulating rna translation via cd154 ca-dinucleotide repeat
|
CN101268194A
(zh)
|
2005-09-20 |
2008-09-17 |
巴斯福植物科学有限公司 |
使用ta-siRNA调控基因表达的方法
|
FR2890859B1
(fr)
*
|
2005-09-21 |
2012-12-21 |
Oreal |
Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
|
US8933043B2
(en)
*
|
2005-09-30 |
2015-01-13 |
St. Jude Children's Research Hospital |
Methods for regulation of p53 translation and function
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
WO2007048046A2
(en)
*
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
GB0521351D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
GB0521716D0
(en)
*
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
US8076307B2
(en)
*
|
2005-10-27 |
2011-12-13 |
National University Corporation NARA Institute of Science and Technology |
Formation/elongation of axon by inhibiting the expression or function of Singar and application to nerve regeneration
|
CA2627025A1
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
WO2007056326A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
EP1951318B1
(en)
*
|
2005-11-07 |
2012-10-17 |
British Columbia Cancer Agency |
Inhibition of autophagy genes in cancer chemotherapy
|
AU2006311730B2
(en)
*
|
2005-11-09 |
2010-12-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
|
US7709456B2
(en)
*
|
2005-11-17 |
2010-05-04 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
US8603991B2
(en)
|
2005-11-18 |
2013-12-10 |
Gradalis, Inc. |
Individualized cancer therapy
|
US8916530B2
(en)
*
|
2005-11-18 |
2014-12-23 |
Gradalis, Inc. |
Individualized cancer therapy
|
US20080125384A1
(en)
*
|
2005-11-21 |
2008-05-29 |
Shuewi Yang |
Simultaneous silencing and restoration of gene function
|
US8153362B2
(en)
*
|
2005-11-24 |
2012-04-10 |
Jichi Medical University |
Mitochondrial function of prohibitin 2 (PHB2)
|
WO2007070682A2
(en)
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
NZ569368A
(en)
*
|
2005-12-22 |
2011-11-25 |
Exegenics Inc D B A Opko Health Inc |
siRNA compositions and methods for regulating the C3 protein in the complement system
|
AR057252A1
(es)
*
|
2005-12-27 |
2007-11-21 |
Alcon Mfg Ltd |
Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
|
US8673873B1
(en)
*
|
2005-12-28 |
2014-03-18 |
Alcon Research, Ltd. |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
|
US8288354B2
(en)
*
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
EP1973574B1
(en)
*
|
2005-12-30 |
2014-04-02 |
Institut Gustave Roussy |
Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
NZ598048A
(en)
*
|
2006-01-17 |
2013-05-31 |
Synthon Biopharmaceuticals Bv |
Compositions and methods for humanization and optimization of n-glycans in plants
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
DK1973946T3
(da)
|
2006-01-20 |
2015-06-22 |
Cell Signaling Technology Inc |
Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
|
US20070259827A1
(en)
*
|
2006-01-25 |
2007-11-08 |
University Of Massachusetts |
Compositions and methods for enhancing discriminatory RNA interference
|
CA2638837A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
WO2007091269A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Quark Pharmaceuticals, Inc. |
NOVEL TANDEM siRNAS
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
FI20060246A0
(fi)
*
|
2006-03-16 |
2006-03-16 |
Jukka Westermarck |
Uusi kasvua stimuloiva proteiini ja sen käyttö
|
WO2007109609A2
(en)
*
|
2006-03-17 |
2007-09-27 |
The Board Of Trustees Of The University Of Illinois |
Method for inhibiting angiogenesis
|
AU2007229161B2
(en)
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
BRPI0709147A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Novartis Ag |
composições de dsrna e métodos para tratamento de infecção por hpv
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
WO2007115047A2
(en)
*
|
2006-03-29 |
2007-10-11 |
Senesco Technologies, Inc. |
Inhibition of hiv replication and expression of p24 with eif-5a
|
CA2648099C
(en)
|
2006-03-31 |
2012-05-29 |
The Brigham And Women's Hospital, Inc |
System for targeted delivery of therapeutic agents
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Eg5遺伝子発現の抑制のための組成物および方法
|
WO2007113331A2
(en)
*
|
2006-04-06 |
2007-10-11 |
Dkfz Deutsches Krebsforschungszentrum |
Method to inhibit the propagation of an undesired cell population
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
ATE460922T1
(de)
*
|
2006-04-07 |
2010-04-15 |
Chimeros Inc |
Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
|
CA2648718A1
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
EP2275543A3
(en)
*
|
2006-04-12 |
2011-03-09 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hepcidin
|
WO2007120842A2
(en)
*
|
2006-04-13 |
2007-10-25 |
Cornell Research Foundation, Inc. |
Methods and compositions for targeting c-rel
|
AU2007238608A1
(en)
|
2006-04-14 |
2007-10-25 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
PL2450437T3
(pl)
|
2006-04-14 |
2017-12-29 |
Cell Signaling Technology Inc |
Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
|
JP4812874B2
(ja)
|
2006-04-28 |
2011-11-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Jcウイルス遺伝子の発現を抑制するための組成物および方法
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
AU2007249329C1
(en)
|
2006-05-11 |
2011-03-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
US20090130212A1
(en)
*
|
2006-05-15 |
2009-05-21 |
Physical Pharmaceutica, Llc |
Composition and improved method for preparation of small particles
|
EP2019691B1
(en)
|
2006-05-15 |
2020-08-12 |
Massachusetts Institute of Technology |
Polymers for functional particles
|
US20070269892A1
(en)
*
|
2006-05-18 |
2007-11-22 |
Nastech Pharmaceutical Company Inc. |
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
EP2392583A1
(en)
*
|
2006-05-19 |
2011-12-07 |
Alnylam Europe AG. |
RNAi modulation of Aha and therapeutic uses thereof
|
KR20090019790A
(ko)
*
|
2006-05-19 |
2009-02-25 |
더 스크립스 리서치 인스티튜트 |
단백질 미스폴딩의 치료
|
EP2584051B1
(en)
*
|
2006-05-22 |
2014-07-16 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expressions of IKK-B gene
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
GB0610542D0
(en)
*
|
2006-05-26 |
2006-07-05 |
Medical Res Council |
Screening method
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
PT2029746E
(pt)
*
|
2006-06-12 |
2012-10-15 |
Exegenics Inc D B A Opko Health Inc |
Composições e métodos para a inibição do sirna de angiogenese
|
US9200275B2
(en)
*
|
2006-06-14 |
2015-12-01 |
Merck Sharp & Dohme Corp. |
Methods and compositions for regulating cell cycle progression
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
WO2008008719A2
(en)
*
|
2006-07-10 |
2008-01-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the myc gene
|
GB0613753D0
(en)
*
|
2006-07-11 |
2006-08-23 |
Norwegian Radium Hospital Res |
Method
|
DK2447275T3
(en)
|
2006-07-13 |
2015-06-29 |
Univ Iowa Res Found |
Methods and reagents for the treatment of age-related macular degeneration
|
JP4756271B2
(ja)
*
|
2006-07-18 |
2011-08-24 |
独立行政法人産業技術総合研究所 |
ガン細胞の老化、アポトーシス誘導剤
|
WO2008009477A2
(en)
|
2006-07-21 |
2008-01-24 |
Silence Therapeutics Ag |
Means for inhibiting the expression of protein kinase 3
|
US20080039415A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
WO2008024844A2
(en)
*
|
2006-08-22 |
2008-02-28 |
The Johns Hopkins University |
Anticancer combination therapies
|
DE102006039479A1
(de)
|
2006-08-23 |
2008-03-06 |
Febit Biotech Gmbh |
Programmierbare Oligonukleotidsynthese
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
CA2663962A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
WO2008036741A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
WO2008036933A2
(en)
*
|
2006-09-21 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the hamp gene
|
JP5352462B2
(ja)
|
2006-09-22 |
2013-11-27 |
ダーマコン, インコーポレイテッド |
二本鎖オリゴヌクレオチド複合体、rna干渉による遺伝子サイレンシング方法、および医薬品組成物
|
US20110150897A1
(en)
*
|
2006-10-11 |
2011-06-23 |
Meyer Thomas F |
Influenza targets
|
US8299040B2
(en)
*
|
2006-10-18 |
2012-10-30 |
Board Of Regents, The University Of Texas System |
Methods for treating cancer targeting transglutaminase
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
EP2407558A1
(en)
|
2006-10-31 |
2012-01-18 |
Noxxon Pharma AG |
Methods for the detection of a single- or double-stranded nucleic acid molecule
|
ATE508191T1
(de)
|
2006-11-01 |
2011-05-15 |
Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct |
Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
US8758998B2
(en)
|
2006-11-09 |
2014-06-24 |
Gradalis, Inc. |
Construction of bifunctional short hairpin RNA
|
US8252526B2
(en)
*
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
US7819842B2
(en)
|
2006-11-21 |
2010-10-26 |
Medtronic, Inc. |
Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
|
US7988668B2
(en)
|
2006-11-21 |
2011-08-02 |
Medtronic, Inc. |
Microsyringe for pre-packaged delivery of pharmaceuticals
|
US8034921B2
(en)
*
|
2006-11-21 |
2011-10-11 |
Alnylam Pharmaceuticals, Inc. |
IRNA agents targeting CCR5 expressing cells and uses thereof
|
JP5271715B2
(ja)
*
|
2006-11-22 |
2013-08-21 |
国立大学法人 東京大学 |
ジスルフィド架橋高分子ミセルを用いた環境応答性siRNAキャリア
|
US20080199475A1
(en)
|
2006-11-27 |
2008-08-21 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US20080171719A1
(en)
*
|
2006-11-28 |
2008-07-17 |
Alcon Manufacturing, Ltd. |
RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
|
US20090048195A1
(en)
*
|
2006-11-30 |
2009-02-19 |
University Of Southern California |
Compositions and methods of sphingosine kinase inhibitors for use thereof in cancer therapy
|
EP2104737B1
(en)
*
|
2006-12-08 |
2013-04-10 |
Asuragen, INC. |
Functions and targets of let-7 micro rnas
|
AU2007333107A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
miR-21 regulated genes and pathways as targets for therapeutic intervention
|
EA200900782A1
(ru)
*
|
2006-12-14 |
2009-12-30 |
Новартис Аг |
Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений
|
CA2671270A1
(en)
*
|
2006-12-29 |
2008-07-17 |
Asuragen, Inc. |
Mir-16 regulated genes and pathways as targets for therapeutic intervention
|
US7754698B2
(en)
*
|
2007-01-09 |
2010-07-13 |
Isis Pharmaceuticals, Inc. |
Modulation of FR-alpha expression
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
US20080171906A1
(en)
*
|
2007-01-16 |
2008-07-17 |
Everaerts Frank J L |
Tissue performance via hydrolysis and cross-linking
|
US20100086526A1
(en)
*
|
2007-01-16 |
2010-04-08 |
Abraham Hochberg |
Nucleic acid constructs and methods for specific silencing of h19
|
CA2925983A1
(en)
|
2007-01-16 |
2008-07-24 |
The University Of Queensland |
Method of inducing an immune response
|
US20090074785A1
(en)
*
|
2007-01-16 |
2009-03-19 |
Smith Jeffrey W |
Compositions and methods for treatment of colorectal cancer
|
WO2008087558A2
(en)
*
|
2007-01-17 |
2008-07-24 |
Institut De Recherches Cliniques De Montreal |
Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
|
CA2676143A1
(en)
|
2007-01-26 |
2008-07-31 |
University Of Louisville Research Foundation, Inc. |
Modification of exosomal components for use as a vaccine
|
WO2008093331A1
(en)
*
|
2007-01-29 |
2008-08-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Antibody conjugates for circumventing multi-drug resistance
|
US20100183696A1
(en)
*
|
2007-01-30 |
2010-07-22 |
Allergan, Inc |
Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
|
MX2009008470A
(es)
|
2007-02-09 |
2009-11-26 |
Univ Northwestern |
Particulas para detectar objetivos intracelulares.
|
US9217129B2
(en)
|
2007-02-09 |
2015-12-22 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
DE102007008596B4
(de)
*
|
2007-02-15 |
2010-09-02 |
Friedrich-Schiller-Universität Jena |
Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
|
CN101646769A
(zh)
*
|
2007-02-20 |
2010-02-10 |
孟山都技术公司 |
无脊椎动物微rna
|
EP2137205A2
(en)
|
2007-02-26 |
2009-12-30 |
Quark Pharmaceuticals, Inc. |
Inhibitors of rtp801 and their use in disease treatment
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
US9018163B2
(en)
*
|
2007-03-02 |
2015-04-28 |
The Trustees Of The University Of Pennsylvania |
Modulating PDX-1 with PCIF1, methods and uses thereof
|
JP2010519913A
(ja)
*
|
2007-03-02 |
2010-06-10 |
エムディーアールエヌエー,インコーポレイテッド |
Wnt遺伝子の発現を抑制するための核酸化合物およびその使用
|
WO2008109357A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting apob gene expression and uses thereof
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
US20080260765A1
(en)
*
|
2007-03-15 |
2008-10-23 |
Johns Hopkins University |
HPV DNA Vaccines and Methods of Use Thereof
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
JP5759673B2
(ja)
|
2007-03-21 |
2015-08-05 |
ブルックヘブン サイエンス アソシエイツ,エルエルシー |
組み合わされたヘアピン−アンチセンス組成物および発現を調節するための方法
|
PE20090064A1
(es)
*
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
AU2008232891B2
(en)
*
|
2007-03-29 |
2012-01-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
EP2144600A4
(en)
|
2007-04-04 |
2011-03-16 |
Massachusetts Inst Technology |
POLY (AMINIC ACID) TARGET MOLECULES
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
JP5258874B2
(ja)
|
2007-04-10 |
2013-08-07 |
キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Rna干渉タグ
|
MX2009011218A
(es)
*
|
2007-04-17 |
2010-02-11 |
Baxter Int |
Microparticulas de acido nucleico para administracion pulmonar.
|
AU2008242583B2
(en)
|
2007-04-23 |
2013-10-10 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of RNA interference agents
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
WO2008137115A1
(en)
|
2007-05-03 |
2008-11-13 |
The Brigham And Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
JP5296328B2
(ja)
*
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
JP2010527243A
(ja)
*
|
2007-05-15 |
2010-08-12 |
ヘリコン セラピューティクス,インコーポレイテッド |
低分子干渉RNA(siRNA)を用いた記憶形成に関わる遺伝子の同定方法
|
CN101808647A
(zh)
*
|
2007-05-15 |
2010-08-18 |
海利空医疗公司 |
通过抑制Gpr12治疗认知障碍的方法
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
EP2162538B1
(en)
|
2007-05-22 |
2016-04-20 |
Arcturus Therapeutics, Inc. |
Oligomers for therapeutics
|
EP2826863B1
(en)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
EP2166843A4
(en)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
|
WO2008153029A1
(ja)
|
2007-06-11 |
2008-12-18 |
Takara Bio Inc. |
特異的遺伝子発現方法
|
US20100273854A1
(en)
*
|
2007-06-15 |
2010-10-28 |
Hagar Kalinski |
Compositions and methods for inhibiting nadph oxidase expression
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
EP2170403B1
(en)
|
2007-06-27 |
2014-04-16 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
EP2172226A4
(en)
*
|
2007-06-29 |
2010-06-30 |
Stelic Institute Regenerative Medicine |
METHOD FOR FIXING AND EXPRESSING A PHYSIOLOGICALLY ACTIVE SUBSTANCE
|
CN101688206B
(zh)
*
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
AU2008273713B2
(en)
*
|
2007-07-10 |
2014-07-03 |
Neurim Pharmaceuticals (1991) Ltd. |
CD44 splice variants in neurodegenerative diseases
|
US8828960B2
(en)
*
|
2007-07-17 |
2014-09-09 |
Idexx Laboratories, Inc. |
Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
|
JP2009033986A
(ja)
*
|
2007-07-31 |
2009-02-19 |
Sumitomo Chemical Co Ltd |
RNA干渉による遺伝子発現抑制のためのターゲット遺伝子としてのcar遺伝子の使用
|
EP2030615A3
(en)
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
US8501929B2
(en)
*
|
2007-08-17 |
2013-08-06 |
Biochrom Pharma Inc. |
PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
|
JP2010537640A
(ja)
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル, インコーポレイテッド |
マイクロrna模倣剤または阻害剤としての非対称性rna二重鎖の組成物
|
US8637477B2
(en)
*
|
2007-08-30 |
2014-01-28 |
Akshaya Bio Inc. |
Antigenic compositions and use of same in the targeted delivery of nucleic acids
|
US20090081789A1
(en)
*
|
2007-08-31 |
2009-03-26 |
Greenville Hospital System |
Activation of nuclear factor kappa B
|
US8183221B2
(en)
|
2007-09-05 |
2012-05-22 |
Medtronic, Inc. |
Suppression of SCN9A gene expression and/or function for the treatment of pain
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
CA2698812A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Nitto Denko Corporation |
Drug carriers
|
JP5049713B2
(ja)
*
|
2007-09-14 |
2012-10-17 |
株式会社コナミデジタルエンタテインメント |
ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
|
WO2009039173A2
(en)
|
2007-09-19 |
2009-03-26 |
Applied Biosystems Inc. |
SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
|
US20100204303A1
(en)
*
|
2007-09-25 |
2010-08-12 |
Idexx Laboratories, Inc. |
Pharmaceutical Compositions for Administering Oligonucleotides
|
US20100136026A1
(en)
*
|
2007-09-26 |
2010-06-03 |
Kerr William G |
Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis
|
PL2644594T3
(pl)
|
2007-09-28 |
2018-01-31 |
Pfizer |
Ukierunkowanie na komórki nowotworowe za pomocą nanocząstek
|
US20120082659A1
(en)
*
|
2007-10-02 |
2012-04-05 |
Hartmut Land |
Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
|
RU2487716C2
(ru)
|
2007-10-03 |
2013-07-20 |
Кварк Фармасьютикалс, Инк. |
Новые структуры малых интерферирующих рнк (sirna)
|
WO2009046397A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agrna and gapmers targeting antisense transcripts
|
BRPI0817664A2
(pt)
|
2007-10-12 |
2015-03-24 |
Massachusetts Inst Technology |
Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
|
EP2203558B1
(en)
|
2007-10-18 |
2016-05-04 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
US20100098664A1
(en)
*
|
2007-11-28 |
2010-04-22 |
Mathieu Jean-Francois Desclaux |
Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression
|
JP2011505144A
(ja)
*
|
2007-11-30 |
2011-02-24 |
ベイラー カレッジ オブ メディシン |
樹状細胞ワクチン組成物およびその使用
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
EP4074344A1
(en)
|
2007-12-04 |
2022-10-19 |
Arbutus Biopharma Corporation |
Targeting lipids
|
AU2008340354B2
(en)
*
|
2007-12-04 |
2014-04-17 |
Alnylam Pharmaceuticals, Inc. |
Folate-iRNA conjugates
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
WO2009074990A2
(en)
*
|
2007-12-12 |
2009-06-18 |
Quark Pharmaceuticals, Inc. |
Rtp801l sirna compounds and methods of use thereof
|
NZ585784A
(en)
*
|
2007-12-13 |
2012-09-28 |
Alnylam Pharmaceuticals Inc |
siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
|
US20090176729A1
(en)
*
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
KR100949791B1
(ko)
*
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도
|
WO2009086156A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Asuragen, Inc. |
Mir-10 regulated genes and pathways as targets for therapeutic intervention
|
EP2242854A4
(en)
*
|
2008-01-15 |
2012-08-15 |
Quark Pharmaceuticals Inc |
COMPOUNDS AND USES THEREOF
|
BRPI0907008A2
(pt)
*
|
2008-01-31 |
2015-07-07 |
Alnylam Pharmaceuticals Inc |
Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
|
EP2260110B1
(en)
*
|
2008-02-08 |
2014-11-12 |
Asuragen, INC. |
miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US7977321B2
(en)
*
|
2008-02-12 |
2011-07-12 |
University Of Tennessee Research Foundation |
Small interfering RNAs targeting feline herpes virus
|
US8288525B2
(en)
*
|
2008-02-12 |
2012-10-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD45 gene
|
US20110207796A1
(en)
*
|
2008-02-13 |
2011-08-25 |
Elan Pharma International Limited |
Alpha-synuclein kinase
|
DE102009043743B4
(de)
|
2009-03-13 |
2016-10-13 |
Friedrich-Schiller-Universität Jena |
Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
|
WO2009103067A2
(en)
*
|
2008-02-14 |
2009-08-20 |
The Children's Hospital Of Philadelphia |
Compositions and methods to treat asthma
|
EA019531B1
(ru)
*
|
2008-03-05 |
2014-04-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ Eg5 И VEGF
|
WO2009111643A2
(en)
*
|
2008-03-06 |
2009-09-11 |
Asuragen, Inc. |
Microrna markers for recurrence of colorectal cancer
|
EP2265291B1
(en)
*
|
2008-03-17 |
2016-10-19 |
The Board of Regents of The University of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
CN102026670A
(zh)
*
|
2008-03-20 |
2011-04-20 |
夸克医药公司 |
用于抑制RTP801的新型siRNA化合物
|
WO2009154835A2
(en)
*
|
2008-03-26 |
2009-12-23 |
Asuragen, Inc. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
WO2009123185A1
(ja)
*
|
2008-03-31 |
2009-10-08 |
独立行政法人産業技術総合研究所 |
Rna干渉効果が高い2本鎖脂質修飾rna
|
TWI348916B
(en)
*
|
2008-04-03 |
2011-09-21 |
Univ Nat Taiwan |
A novel treatment tool for cancer: rna interference of bcas2
|
WO2009126726A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
EP3604533A1
(en)
|
2008-04-11 |
2020-02-05 |
Arbutus Biopharma Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
WO2009126913A1
(en)
|
2008-04-11 |
2009-10-15 |
Cedars-Sinai Medical Center |
Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
|
US8278287B2
(en)
*
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
US7875711B2
(en)
|
2008-04-17 |
2011-01-25 |
Alnylam Pharamaceuticals, Inc. |
Compositions and methods for inhibiting expression of XBP-1 gene
|
US20090285861A1
(en)
*
|
2008-04-17 |
2009-11-19 |
Tzyy-Choou Wu |
Tumor cell-based cancer immunotherapeutic compositions and methods
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
JP5773366B2
(ja)
|
2008-04-21 |
2015-09-02 |
ティシュー リジェネレイション セラピューティックス、インコーポレイテッド |
生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
WO2009134443A2
(en)
*
|
2008-05-02 |
2009-11-05 |
The Brigham And Women's Hospital, Inc. |
Rna-induced translational silencing and cellular apoptosis
|
EP2285960B1
(en)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
US20100009451A1
(en)
*
|
2008-05-30 |
2010-01-14 |
Sigma Aldrich Company |
Compositions and methods for specifically silencing a target nucleic acid
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
US20090305611A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Flow International Corporation |
Device and method for improving accuracy of a high-pressure fluid jet apparatus
|
JP5524189B2
(ja)
|
2008-06-06 |
2014-06-18 |
クォーク ファーマシューティカルズ インコーポレーティッド |
耳障害治療のための組成物および方法
|
EP2235177B1
(en)
*
|
2008-06-13 |
2012-07-18 |
RiboxX GmbH |
Method for enzymatic synthesis of chemically modified rna
|
WO2010005741A1
(en)
*
|
2008-06-16 |
2010-01-14 |
Georgia Tech Research Corporation |
Nanogels for cellular delivery of therapeutics
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
US20110184046A1
(en)
|
2008-07-11 |
2011-07-28 |
Dinah Wen-Yee Sah |
Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
US8039658B2
(en)
*
|
2008-07-25 |
2011-10-18 |
Air Products And Chemicals, Inc. |
Removal of trace arsenic impurities from triethylphosphate (TEPO)
|
US8212019B2
(en)
*
|
2008-07-30 |
2012-07-03 |
University Of Massachusetts |
Nucleic acid silencing sequences
|
EP2326351B1
(en)
|
2008-08-19 |
2017-12-27 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
EP2331141B1
(en)
|
2008-08-25 |
2016-01-06 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
CA2737180C
(en)
*
|
2008-09-15 |
2019-02-19 |
Children's Medical Center Corporation |
Modulation of bcl11a for treatment of hemoglobinopathies
|
EP2949752B1
(en)
|
2008-09-22 |
2017-12-20 |
RXi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
EP3587434A1
(en)
|
2008-09-23 |
2020-01-01 |
Alnylam Pharmaceuticals Inc. |
Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
WO2010042547A1
(en)
|
2008-10-06 |
2010-04-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of an rna from west nile virus
|
WO2010042292A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
|
US9388413B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
US9388414B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
US8802646B2
(en)
*
|
2008-10-08 |
2014-08-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
|
US9149492B2
(en)
|
2008-10-08 |
2015-10-06 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
|
PL2350043T3
(pl)
|
2008-10-09 |
2014-09-30 |
Tekmira Pharmaceuticals Corp |
Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
WO2010045384A2
(en)
*
|
2008-10-15 |
2010-04-22 |
Somagenics Inc. |
Short hairpin rnas for inhibition of gene expression
|
US9458472B2
(en)
*
|
2008-10-15 |
2016-10-04 |
Massachusetts Institute Of Technology |
Detection and destruction of cancer cells using programmed genetic vectors
|
CN103937793B
(zh)
|
2008-10-20 |
2017-08-11 |
阿尔尼拉姆医药品有限公司 |
抑制运甲状腺素蛋白表达的组合物和方法
|
EP2350277A1
(en)
*
|
2008-10-23 |
2011-08-03 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
|
US20110190380A1
(en)
*
|
2008-10-23 |
2011-08-04 |
Elena Feinstein |
Methods for delivery of sirna to bone marrow cells and uses thereof
|
EP3808177A1
(en)
|
2008-11-10 |
2021-04-21 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
US20100179213A1
(en)
*
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
EP2365804B1
(en)
*
|
2008-11-13 |
2015-05-06 |
Modgene, Llc |
Reduction of amyloid-beta load in non-brain tissue
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
AU2009316853A1
(en)
|
2008-11-21 |
2010-05-27 |
Isis Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer
|
EP2365803B1
(en)
|
2008-11-24 |
2017-11-01 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
EP2191834A1
(en)
*
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
CN104673798B
(zh)
|
2008-12-03 |
2018-03-20 |
阿克丘勒斯治疗公司 |
UsiRNA复合物
|
US20100291188A1
(en)
*
|
2008-12-04 |
2010-11-18 |
Musc Foundation For Research Development |
Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
|
WO2010065834A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
EP3225281A1
(en)
*
|
2008-12-10 |
2017-10-04 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
EP2356236B1
(en)
*
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
|
WO2010067882A1
(ja)
*
|
2008-12-12 |
2010-06-17 |
株式会社クレハ |
癌及び喘息治療のための医薬組成物
|
US20100233172A1
(en)
*
|
2008-12-16 |
2010-09-16 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
CN102300556B
(zh)
|
2008-12-26 |
2015-04-29 |
株式会社三养生物制药 |
含有阴离子药物的药物组合物及其制备方法
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US8980820B2
(en)
*
|
2009-01-19 |
2015-03-17 |
The Research Foundation For The State University Of New York |
Fatty acid binding proteins as drug targets for endocannabinoids
|
CA2750044A1
(en)
*
|
2009-01-20 |
2010-07-29 |
Vib Vzw |
Phd2 inhibition for blood vessel normalization, and uses thereof
|
US9023820B2
(en)
|
2009-01-26 |
2015-05-05 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein C-III expression
|
KR20110100316A
(ko)
*
|
2009-02-03 |
2011-09-09 |
에프. 호프만-라 로슈 아게 |
Ptp1b 유전자의 발현을 억제하기 위한 조성물 및 방법
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
HUE035769T2
(en)
|
2009-02-12 |
2018-05-28 |
Cell Signaling Technology Inc |
Mutant ROS expression in human liver cancer
|
US20120041049A1
(en)
|
2009-02-24 |
2012-02-16 |
Riboxx Gmbh |
Design of small-interfering rna
|
CA2753975C
(en)
|
2009-03-02 |
2017-09-26 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
CA2755773A1
(en)
*
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
CN102378766A
(zh)
|
2009-03-23 |
2012-03-14 |
夸克医药公司 |
治疗癌症和纤维化疾病的化合物组合物和方法
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
EP2421972A2
(en)
*
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
US8367350B2
(en)
|
2009-04-29 |
2013-02-05 |
Morehouse School Of Medicine |
Compositions and methods for diagnosis, prognosis and management of malaria
|
US8933049B2
(en)
*
|
2009-05-05 |
2015-01-13 |
Medical Diagnostic Laboratories, Llc |
Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
|
WO2010128465A1
(en)
|
2009-05-05 |
2010-11-11 |
Beeologics, Llc |
Prevention and treatment of nosema disease in bees
|
WO2010129791A1
(en)
|
2009-05-06 |
2010-11-11 |
University Of Medicine And Dentistry Of New Jersey |
Rna targeting in alpha-synucleinopathies
|
WO2010130771A2
(en)
*
|
2009-05-15 |
2010-11-18 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
|
WO2011005363A2
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
WO2010135669A1
(en)
*
|
2009-05-22 |
2010-11-25 |
Sabiosciences Corporation |
Arrays and methods for reverse genetic functional analysis
|
US9200276B2
(en)
|
2009-06-01 |
2015-12-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
|
US20120083519A1
(en)
*
|
2009-06-03 |
2012-04-05 |
Djillali Sahali |
Methods For Diagnosing And Treating A Renal Disease In An Individual
|
AU2010256356B2
(en)
|
2009-06-05 |
2015-07-16 |
University Of Florida Research Foundation, Inc. |
Isolation and targeted suppression of lignin biosynthetic genes from sugarcane
|
DK3276004T3
(da)
|
2009-06-08 |
2020-04-06 |
Quark Pharmaceuticals Inc |
Fremgangsmåder til behandling af kronisk nyresygdom
|
PL3431076T3
(pl)
|
2009-06-10 |
2022-01-31 |
Arbutus Biopharma Corporation |
Ulepszona formulacja lipidowa
|
EP2440666B1
(en)
|
2009-06-10 |
2017-03-01 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
KR20120050429A
(ko)
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
|
US20100323018A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
US20100324124A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Compositions and methods relating to DNA-based particles
|
GB0910723D0
(en)
*
|
2009-06-22 |
2009-08-05 |
Sylentis Sau |
Novel drugs for inhibition of gene expression
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
US8871730B2
(en)
|
2009-07-13 |
2014-10-28 |
Somagenics Inc. |
Chemical modification of short small hairpin RNAs for inhibition of gene expression
|
US8716464B2
(en)
*
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
SI2769737T1
(sl)
|
2009-07-20 |
2017-06-30 |
Bristol-Myers Squibb Company |
Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni
|
US8840889B2
(en)
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
NZ599005A
(en)
|
2009-08-24 |
2014-11-28 |
Phigenix Inc |
Targeting pax2 for the treatment of breast cancer
|
US20120263709A1
(en)
|
2009-09-10 |
2012-10-18 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic diseases
|
EP2295543A1
(en)
|
2009-09-11 |
2011-03-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Method for the preparation of an influenza virus
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
CN102639115A
(zh)
|
2009-09-15 |
2012-08-15 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制eg5和vegf基因的表达的方法
|
US8916693B2
(en)
|
2009-09-17 |
2014-12-23 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
EP2480668A2
(en)
*
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
JP5866119B2
(ja)
|
2009-10-30 |
2016-02-17 |
ノースウェスタン ユニバーシティ |
鋳型ナノ複合体
|
EP2496238A4
(en)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR)
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
CN102666856B
(zh)
|
2009-11-08 |
2016-04-06 |
夸克制药公司 |
定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
|
EP2501800A4
(en)
|
2009-11-17 |
2013-05-22 |
Musc Found For Res Dev |
HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN
|
WO2011066475A1
(en)
|
2009-11-26 |
2011-06-03 |
Quark Pharmaceuticals, Inc. |
Sirna compounds comprising terminal substitutions
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
CN102741410B
(zh)
*
|
2009-12-09 |
2016-11-16 |
日东电工株式会社 |
Hsp47表达的调节
|
US8778904B2
(en)
|
2009-12-09 |
2014-07-15 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the CNS
|
US8785371B2
(en)
|
2009-12-10 |
2014-07-22 |
Cedars-Sinai Medical Center |
Drug delivery of temozolomide for systemic based treatment of cancer
|
EP2336171A1
(en)
|
2009-12-11 |
2011-06-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel targets for the treatment of proliferative diseases
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
US8293718B2
(en)
|
2009-12-18 |
2012-10-23 |
Novartis Ag |
Organic compositions to treat HSF1-related diseases
|
WO2011076873A1
(en)
|
2009-12-23 |
2011-06-30 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Influenza targets
|
SG188160A1
(en)
|
2009-12-23 |
2013-03-28 |
Gradalis Inc |
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
US20130023578A1
(en)
|
2009-12-31 |
2013-01-24 |
Samyang Biopharmaceuticals Corporation |
siRNA for inhibition of c-Met expression and anticancer composition containing the same
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
TW201124159A
(en)
*
|
2010-01-07 |
2011-07-16 |
Univ Nat Cheng Kung |
Small interference RNA molecule and applications thereof
|
US9200277B2
(en)
*
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
WO2011088058A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expressions of factor vii and pten genes
|
DE102010004957A1
(de)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
US8722641B2
(en)
|
2010-01-29 |
2014-05-13 |
St. Jude Children's Research Hospital |
Oligonucleotides which inhibit p53 induction in response to cellular stress
|
EP2534489A1
(en)
|
2010-02-10 |
2012-12-19 |
Novartis AG |
Methods and compounds for muscle growth
|
AU2011227050B2
(en)
|
2010-03-19 |
2016-12-08 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
CN110042099A
(zh)
|
2010-03-24 |
2019-07-23 |
菲奥医药公司 |
皮肤与纤维化症候中的rna干扰
|
US8455455B1
(en)
|
2010-03-31 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes involved in hemorrhagic fever
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
WO2011133658A1
(en)
|
2010-04-22 |
2011-10-27 |
Boston Medical Center Corporation |
Compositions and methods for targeting and delivering therapeutics into cells
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
PT2563920T
(pt)
|
2010-04-29 |
2017-05-26 |
Ionis Pharmaceuticals Inc |
Modulação da expressão de transtirretina
|
US20110269807A1
(en)
|
2010-04-30 |
2011-11-03 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
ES2596431T3
(es)
|
2010-05-04 |
2017-01-09 |
The Brigham And Women's Hospital, Inc. |
Antagonista de cadherina-11 para el tratamiento de fibrosis
|
US8563243B2
(en)
*
|
2010-05-12 |
2013-10-22 |
University Of South Carolina |
Methods for affecting homology-directed DNA double stranded break repair
|
CN107080839A
(zh)
|
2010-05-26 |
2017-08-22 |
西莱克塔生物科技公司 |
多价的合成纳米载体疫苗
|
EP2390327A1
(en)
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
DE102010022937A1
(de)
|
2010-06-04 |
2011-12-08 |
Universitätsklinikum Jena |
Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung
|
US20130236968A1
(en)
|
2010-06-21 |
2013-09-12 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
NZ604094A
(en)
|
2010-06-24 |
2014-11-28 |
Quark Pharmaceuticals Inc |
Double stranded rna compounds to rhoa and use thereof
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
US8933051B2
(en)
|
2010-09-30 |
2015-01-13 |
University Of Zurich |
Treatment of B-cell lymphoma with microRNA
|
WO2013052006A1
(en)
*
|
2010-10-07 |
2013-04-11 |
Agency For Science, Technology And Research (A*Star) |
Parp-1 inhibitors
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
ES2732929T3
(es)
|
2010-10-22 |
2019-11-26 |
Olix Pharmaceuticals Inc |
Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
AU2011338682B2
(en)
|
2010-12-06 |
2017-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising threose modifications
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
US9617542B2
(en)
*
|
2010-12-14 |
2017-04-11 |
The United States of America, as representd by The Secretary of Agriculture |
Lepidopteran moth control using double-stranded RNA constructs
|
US9623041B2
(en)
|
2010-12-30 |
2017-04-18 |
Cedars-Sinai Medical Center |
Polymalic acid-based nanobiopolymer compositions
|
GB2559498B
(en)
|
2011-01-10 |
2018-10-24 |
Univ Michigan Regents |
Stem cell factor inhibitor
|
EP3202760B1
(en)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
DE102011009470A1
(de)
|
2011-01-21 |
2012-08-09 |
Friedrich-Schiller-Universität Jena |
Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit
|
BR112013019803A2
(pt)
|
2011-02-02 |
2019-06-11 |
Excaliard Pharmaceuticals Inc |
método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
|
WO2012106586A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
SG10201604479YA
(en)
*
|
2011-03-03 |
2016-07-28 |
Quark Pharmaceuticals Inc |
Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
|
US9233121B2
(en)
*
|
2011-03-11 |
2016-01-12 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the treatment of cancer
|
JP2014515012A
(ja)
|
2011-03-15 |
2014-06-26 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
血管関連黄斑症およびその症状の診断および治療方法
|
US9458456B2
(en)
*
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
CA2832073A1
(en)
|
2011-04-12 |
2012-10-18 |
Terrence R. Burke |
Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
|
JP5951752B2
(ja)
|
2011-04-13 |
2016-07-13 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Ptp1b発現のアンチセンス調節
|
US8716257B2
(en)
*
|
2011-04-15 |
2014-05-06 |
Sutter West Bay Hospitals |
CMV gene products promote cancer stem cell growth
|
WO2012142622A1
(en)
|
2011-04-15 |
2012-10-18 |
Molecular Transfer, Inc. |
Agents for improved delivery of nucleic acids to eukaryotic cells
|
CA2836898A1
(en)
|
2011-05-20 |
2012-11-29 |
Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
PL3446714T3
(pl)
|
2011-06-02 |
2021-11-22 |
University Of Louisville Research Foundation, Inc. |
Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
|
KR102540778B1
(ko)
|
2011-06-21 |
2023-06-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
WO2012177921A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
|
EP2723758B1
(en)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
LT2729173T
(lt)
|
2011-07-06 |
2016-10-10 |
Sykehuset Sorlandet Hf |
Egfr taikinių terapija
|
WO2013006861A1
(en)
|
2011-07-07 |
2013-01-10 |
University Of Georgia Research Foundation, Inc. |
Sorghum grain shattering gene and uses thereof in altering seed dispersal
|
US8853181B2
(en)
|
2011-07-21 |
2014-10-07 |
Albert Einstein College Of Medicine Of Yeshiva University |
Fidgetin-like 2 as a target to enhance wound healing
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
DE102011118024A1
(de)
|
2011-08-01 |
2013-02-07 |
Technische Universität Dresden |
Inhibitor der Expression der Pro-Caspase 1
|
CA3065098C
(en)
|
2011-09-06 |
2023-08-08 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
The mirna-212/132 family as a therapeutic target
|
CA2847888A1
(en)
|
2011-09-09 |
2013-03-14 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
CA2849476A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
US9951349B2
(en)
|
2011-09-27 |
2018-04-24 |
Yale University |
Compositions and methods for transient expression of recombinant RNA
|
AU2012325997C1
(en)
|
2011-10-18 |
2018-07-05 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
EP2776565A1
(en)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
EP2592146A3
(en)
|
2011-11-14 |
2013-07-24 |
Silenseed Ltd |
Methods and compositions for treating prostate cancer
|
DK3301177T3
(da)
|
2011-11-18 |
2020-06-15 |
Alnylam Pharmaceuticals Inc |
Rnai-midler, sammensætninger og fremgangsmåder til anvendelse deraf til behandling af transthyretin (ttr)-forbundne sygdomme
|
WO2013082529A1
(en)
|
2011-12-02 |
2013-06-06 |
Yale University |
Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
|
CN104080480A
(zh)
|
2012-01-01 |
2014-10-01 |
奇比艾企业有限公司 |
用于选择性递送治疗剂和诊断剂的endo180靶向微粒
|
WO2013103401A1
(en)
*
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
BR112014016937A2
(pt)
|
2012-01-12 |
2017-06-13 |
Quark Pharmaceuticals Inc |
terapia de combinação para o tratamento de desordens de audição e do equilíbrio
|
US20150126438A1
(en)
|
2012-01-24 |
2015-05-07 |
Beth Israel Deaconess Medical Center, Inc. |
Novel ChREBP Isoforms and Methods Using the Same
|
WO2013138463A1
(en)
|
2012-03-14 |
2013-09-19 |
University Of Central Florida Research Foundation, Inc. |
Neurofibromatoses therapeutic agents and screening for same
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
EP3336181B1
(en)
|
2012-04-18 |
2022-01-12 |
Cell Signaling Technology, Inc. |
Egfr and ros1 in cancer
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
JP6139671B2
(ja)
|
2012-05-22 |
2017-05-31 |
オリックス ファーマシューティカルズ インコーポレイテッドOlix Pharmaceuticals Inc. |
細胞内貫通能を持ってrna干渉を誘導する核酸分子およびその用途
|
US9726661B2
(en)
|
2012-07-06 |
2017-08-08 |
Institut Gustave-Roussy |
Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
CA2883130A1
(en)
*
|
2012-08-31 |
2014-03-06 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
SG11201501385UA
(en)
|
2012-09-05 |
2015-03-30 |
Sylentis Sau |
Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
ES2704855T3
(es)
|
2012-09-12 |
2019-03-20 |
Quark Pharmaceuticals Inc |
Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
|
DK2895607T3
(da)
|
2012-09-12 |
2021-05-25 |
Quark Pharmaceuticals Inc |
Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
|
BR112015006176B1
(pt)
|
2012-09-21 |
2023-04-18 |
Intensity Therapeutics, Inc |
Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
|
EP3795694A3
(en)
*
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
WO2014068072A1
(en)
|
2012-10-31 |
2014-05-08 |
Institut Gustave-Roussy |
Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
|
US9856477B2
(en)
*
|
2012-11-13 |
2018-01-02 |
Codiak Biosciences, Inc. |
Delivery of therapeutic agent
|
DE102012022596B4
(de)
|
2012-11-15 |
2017-05-04 |
Friedrich-Schiller-Universität Jena |
Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung
|
ES2879430T3
(es)
|
2012-11-15 |
2021-11-22 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
|
CN109554350B
(zh)
|
2012-11-27 |
2022-09-23 |
儿童医疗中心有限公司 |
用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
|
WO2014093688A1
(en)
|
2012-12-12 |
2014-06-19 |
1Massachusetts Institute Of Technology |
Compositions and methods for functional nucleic acid delivery
|
BR112015013849A2
(pt)
|
2012-12-21 |
2017-07-11 |
Sykehuset Soerlandet Hf |
terapia direcionada a egfr de distúrbios neurológicos e dor
|
US9206423B2
(en)
*
|
2012-12-30 |
2015-12-08 |
The Regents Of The University Of California |
Methods of modulating compliance of the trabecular meshwork
|
WO2014113541A1
(en)
|
2013-01-16 |
2014-07-24 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
DE102013003869B4
(de)
|
2013-02-27 |
2016-11-24 |
Friedrich-Schiller-Universität Jena |
Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
|
KR102310921B1
(ko)
|
2013-03-14 |
2021-10-13 |
다이서나 파마수이티컬, 인크. |
음이온성 약제를 제형화하는 방법
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
WO2014144721A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Treating th2-mediated diseases by inhibition of bromodomains
|
EP2971094B1
(en)
*
|
2013-03-15 |
2021-09-15 |
Novartis AG |
Biomarkers associated with brm inhibition
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
EP2997373A1
(en)
|
2013-05-17 |
2016-03-23 |
MedImmune, LLC |
Receptors for b7-h4
|
CA2916533C
(en)
|
2013-06-25 |
2022-12-20 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
WO2015006554A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
BR112016000555B1
(pt)
|
2013-07-19 |
2022-12-27 |
Monsanto Technology Llc |
Método para controlar uma infestação da espécie de leptinotarsa em uma planta, composição inseticida e construção de dna recombinante
|
US10711106B2
(en)
|
2013-07-25 |
2020-07-14 |
The University Of Chicago |
High aspect ratio nanofibril materials
|
US9889200B2
(en)
|
2013-07-31 |
2018-02-13 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
WO2015031679A2
(en)
|
2013-08-28 |
2015-03-05 |
Isis Pharmaceuticals, Inc. |
Modulation of prekallikrein (pkk) expression
|
EP3808338A1
(en)
|
2013-09-11 |
2021-04-21 |
Eagle Biologics, Inc. |
Liquid protein formulations containing ionic liquids
|
CN105764513A
(zh)
|
2013-09-18 |
2016-07-13 |
堪培拉大学 |
干细胞调控ii
|
EP3052107B1
(en)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organic compounds to treat hepatitis b virus
|
WO2015051045A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
|
EP2865758A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
|
EP2865756A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
|
EP2865757A1
(en)
|
2013-10-22 |
2015-04-29 |
Sylentis, S.A.U. |
siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
|
AU2014346457A1
(en)
|
2013-11-11 |
2016-06-02 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
WO2015077566A1
(en)
|
2013-11-21 |
2015-05-28 |
Huang Zhen |
Methods for structural determination of selenium derivatized nucleic acid complexes
|
CN106061488B
(zh)
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
US10150965B2
(en)
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
CN104830906B
(zh)
|
2014-02-12 |
2018-09-04 |
北京维通达生物技术有限公司 |
一种重编程获得功能性人肝脏实质细胞的方法
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
PT3116902T
(pt)
|
2014-03-11 |
2020-04-03 |
Cellectis |
Método para gerar células t compatíveis para transplante alogénico
|
EP3119887B1
(en)
*
|
2014-03-20 |
2019-02-20 |
Oommen Varghese |
Improved small interfering ribonucleic acid molecules
|
AU2015236215B2
(en)
|
2014-03-25 |
2020-03-19 |
Arcturus Therapeutics, Inc. |
UNA oligomers having reduced off-target effects in gene silencing
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
JP6771387B2
(ja)
|
2014-03-25 |
2020-10-21 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー
|
JP6622214B2
(ja)
|
2014-04-01 |
2019-12-18 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Sod−1発現を調節するための組成物
|
US11091770B2
(en)
|
2014-04-01 |
2021-08-17 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
MX2016013832A
(es)
|
2014-04-25 |
2017-03-09 |
Children´S Medical Center Corp |
Composiciones y metodos para tratar hemoglobinopatias.
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
DK3137091T3
(da)
|
2014-05-01 |
2021-01-25 |
Ionis Pharmaceuticals Inc |
Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
|
KR102492647B1
(ko)
|
2014-05-02 |
2023-01-30 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
항-lyst 면역조절을 위한 조성물 및 방법
|
JP6763780B2
(ja)
|
2014-05-12 |
2020-09-30 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
合成脳浸透遺伝子ベクターの操作
|
US10335500B2
(en)
|
2014-05-12 |
2019-07-02 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
WO2015184105A1
(en)
|
2014-05-29 |
2015-12-03 |
Trustees Of Dartmouth College |
Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases
|
EP3508198A1
(en)
|
2014-06-04 |
2019-07-10 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
CN104120127B
(zh)
*
|
2014-07-01 |
2016-09-21 |
清华大学 |
分离的寡核苷酸及其应用
|
US10378012B2
(en)
|
2014-07-29 |
2019-08-13 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
WO2016019126A1
(en)
|
2014-07-30 |
2016-02-04 |
The Research Foundation For The State University Of New York |
System and method for delivering genetic material or protein to cells
|
US20200230251A1
(en)
|
2014-08-14 |
2020-07-23 |
Friedrich-Schiller-Universitaet Jena |
Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
|
CN107106517A
(zh)
|
2014-08-25 |
2017-08-29 |
堪培拉大学 |
用于调节癌干细胞的组合物及其用途
|
KR102631505B1
(ko)
|
2014-08-29 |
2024-02-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
JP6841753B2
(ja)
|
2014-09-15 |
2021-03-10 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
|
CA2962406A1
(en)
|
2014-09-25 |
2016-03-31 |
Cold Spring Harbor Laboratory |
Treatment of rett syndrome
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
US10538762B2
(en)
*
|
2014-10-14 |
2020-01-21 |
The Board Of Regents Of The University Of Texas System |
Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
|
EP3209794A1
(en)
|
2014-10-22 |
2017-08-30 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
Modulating adipose tissue and adipogenesis
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
AU2015346281B2
(en)
|
2014-11-12 |
2021-12-02 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
WO2016081621A1
(en)
|
2014-11-18 |
2016-05-26 |
Yale University |
Formulations for targeted release of agents under low ph conditions and methods of use thereof
|
CA2968531A1
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US20190002876A1
(en)
*
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
US20180002702A1
(en)
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
CN108064288B
(zh)
|
2015-01-22 |
2021-11-26 |
孟山都技术公司 |
用于控制叶甲属的组合物和方法
|
US10519447B2
(en)
|
2015-04-01 |
2019-12-31 |
Arcturus Therapeutics, Inc. |
Therapeutic UNA oligomers and uses thereof
|
EP3283631A1
(en)
|
2015-04-13 |
2018-02-21 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2016168197A1
(en)
|
2015-04-15 |
2016-10-20 |
Yale University |
Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
EP3294873B2
(en)
|
2015-05-08 |
2024-09-18 |
The Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
US10933049B2
(en)
|
2015-06-03 |
2021-03-02 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
IL256175B1
(en)
|
2015-06-10 |
2024-06-01 |
Univ Texas |
Using exosomes to treat the disease
|
US10550387B2
(en)
*
|
2015-06-30 |
2020-02-04 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for a lung disease and/or method for screening for the same
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
EP3862005A1
(en)
|
2015-07-06 |
2021-08-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
TTR関連疾患を治療または予防するためのトランスサイレチン(TTR)iRNA組成物およびその使用方法
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
CA2995995A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
MA44908A
(fr)
|
2015-09-08 |
2018-07-18 |
Sylentis Sau |
Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
|
GB201516685D0
(en)
*
|
2015-09-21 |
2015-11-04 |
Varghese Oommen P And Oommen Oommen P |
Nucleic acid molecules with enhanced activity
|
CN108601823A
(zh)
|
2015-09-23 |
2018-09-28 |
麻省理工学院 |
用于改性树枝状聚合物纳米颗粒疫苗递送的组合物和方法
|
US10383935B2
(en)
|
2015-09-23 |
2019-08-20 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
US10086063B2
(en)
|
2015-09-23 |
2018-10-02 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
EP4435105A2
(en)
|
2015-09-29 |
2024-09-25 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
ES2974107T3
(es)
|
2015-10-07 |
2024-06-25 |
Apellis Pharmaceuticals Inc |
Regímenes de dosificación
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
|
KR20180071362A
(ko)
|
2015-11-16 |
2018-06-27 |
올릭스 주식회사 |
MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료
|
WO2017095751A1
(en)
|
2015-12-02 |
2017-06-08 |
Partikula Llc |
Compositions and methods for modulating cancer cell metabolism
|
US11299537B2
(en)
|
2015-12-10 |
2022-04-12 |
Fibrogen, Inc. |
Methods for treatment of motor neuron diseases
|
CN108366964B
(zh)
|
2015-12-18 |
2022-04-08 |
三养控股公司 |
制备含阴离子药物的聚合物胶束的方法
|
BR102017001164A2
(pt)
|
2016-01-26 |
2019-03-06 |
Embrapa - Empresa Brasileira De Pesquisa Agropecuária |
Composições de rna de fita dupla para controle de diaphorina citri e métodos de uso.
|
EP3408391A4
(en)
|
2016-01-31 |
2019-08-28 |
University of Massachusetts |
BRANCHED OLIGONUCLEOTIDES
|
CA3022874A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
|
CA3022877A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
|
CN109069520A
(zh)
|
2016-02-25 |
2018-12-21 |
应用生物实验室公司 |
保护空气传播的病原体和刺激物的组合物和方法
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
WO2017147594A1
(en)
|
2016-02-26 |
2017-08-31 |
Yale University |
COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
|
WO2017151623A1
(en)
|
2016-03-01 |
2017-09-08 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
US11072777B2
(en)
|
2016-03-04 |
2021-07-27 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
|
EP3426261A4
(en)
|
2016-03-07 |
2020-03-25 |
Arrowhead Pharmaceuticals, Inc. |
TARGETED LIGANDS FOR THERAPEUTIC CONNECTIONS
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
WO2017176894A1
(en)
|
2016-04-06 |
2017-10-12 |
Ohio State Innovation Foundation |
Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
|
CN109072238B
(zh)
|
2016-04-11 |
2022-05-24 |
奥利克斯医药有限公司 |
使用靶向结缔组织生长因子的rna复合物治疗特发性肺纤维化
|
AU2017250017B2
(en)
|
2016-04-14 |
2022-12-22 |
Benitec IP Holdings Inc. |
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
|
WO2017189870A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
RU2627179C1
(ru)
*
|
2016-07-28 |
2017-08-03 |
федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
ТЕСТ-СИСТЕМА ДЛЯ ОПРЕДЕЛЕНИЯ РНК ИНТЕРФЕРОНА λ, ИНТЕРЛЕЙКИНА IL23 И ПРОТИВОВИРУСНОГО БЕЛКА MxA
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
KR20190037273A
(ko)
|
2016-08-03 |
2019-04-05 |
에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 |
Tlr9 표적 치료제
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
EP4101859A1
(en)
|
2016-09-02 |
2022-12-14 |
Dicerna Pharmaceuticals, Inc. |
4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same
|
AU2017320582B2
(en)
|
2016-09-02 |
2023-11-16 |
Arrowhead Pharmaceuticals, Inc |
Targeting ligands
|
EP3516062A1
(en)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Myostatin irna compositions and methods of use thereof
|
WO2018062510A1
(ja)
*
|
2016-09-29 |
2018-04-05 |
国立大学法人東京医科歯科大学 |
オーバーハングを有する二本鎖核酸複合体
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018107096A1
(en)
|
2016-12-08 |
2018-06-14 |
University Of Utah Research Foundation |
Staufen1 agents and associated methods
|
WO2018112470A1
(en)
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
IL267959B2
(en)
|
2017-01-10 |
2024-07-01 |
Arrowhead Pharmaceuticals Inc |
Alpha-1 antitrypsin (AAT) RNAi agents, preparations containing AAT RNAi agents and their uses
|
KR20190108167A
(ko)
*
|
2017-02-10 |
2019-09-23 |
성균관대학교산학협력단 |
Rna 간섭을 위한 긴 이중가닥 rna
|
DE102017103383A1
(de)
|
2017-02-20 |
2018-08-23 |
aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) |
System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
|
US11613754B2
(en)
*
|
2017-02-20 |
2023-03-28 |
Northwestern University |
Toxic RNAi active seed sequences for killing cancer cells
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
US11261441B2
(en)
|
2017-03-29 |
2022-03-01 |
Bluebird Bio, Inc. |
Vectors and compositions for treating hemoglobinopathies
|
JP2020516607A
(ja)
|
2017-04-07 |
2020-06-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. |
投与レジメンならびに関連組成物および方法
|
WO2018191751A1
(en)
|
2017-04-14 |
2018-10-18 |
Arizona Board Of Regents On Behalf Of The University Of Arizonia |
Compositions and methods for treating pulmonary fibrosis
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
WO2018218135A1
(en)
|
2017-05-25 |
2018-11-29 |
The Children's Medical Center Corporation |
Bcl11a guide delivery
|
WO2018236995A2
(en)
*
|
2017-06-20 |
2018-12-27 |
Dana-Farber Cancer Institute, Inc. |
METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS
|
JP7406793B2
(ja)
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
2テイル自己デリバリー型siRNAおよび関連方法
|
AU2018297262A1
(en)
|
2017-07-06 |
2020-02-27 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
|
WO2019014491A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals, Inc. |
METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE))
|
US11110114B2
(en)
|
2017-07-17 |
2021-09-07 |
Oxford University Innovation Limited |
Dinucleotides
|
US11104700B2
(en)
|
2017-07-17 |
2021-08-31 |
Oxford University Innovation Limited |
Oligonucleotides
|
CR20200108A
(es)
|
2017-09-11 |
2020-06-28 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
AU2018336806A1
(en)
|
2017-09-19 |
2020-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
IL282881B1
(en)
|
2017-10-20 |
2024-06-01 |
Dicerna Pharmaceuticals Inc |
Methods for treating hepatitis B infection
|
WO2019100053A1
(en)
|
2017-11-20 |
2019-05-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2α to improve muscle generation and repair
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
RU2020121752A
(ru)
|
2017-12-01 |
2021-12-30 |
ТЕХАССКАЯ УНИВЕРСИТЕТСКАЯ СИСТЕМА А энд М |
Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты
|
MX2020005860A
(es)
|
2017-12-06 |
2020-09-09 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
|
AU2018392782B2
(en)
|
2017-12-21 |
2023-08-31 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
WO2019126691A1
(en)
|
2017-12-21 |
2019-06-27 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
US10960086B2
(en)
|
2017-12-28 |
2021-03-30 |
Augusta University Research Institute, Inc. |
Aptamer compositions and methods of use thereof
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
MX2020007066A
(es)
|
2018-01-05 |
2020-09-09 |
Dicerna Pharmaceuticals Inc |
Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.
|
AU2019209324A1
(en)
|
2018-01-16 |
2020-07-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting ALDH2 expression
|
PE20211197A1
(es)
|
2018-02-09 |
2021-07-01 |
Genentech Inc |
Oligonucleotidos para modular la expresion de tmem106b
|
JP2021522808A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチド治療剤の超並列発見方法
|
JP7467355B2
(ja)
|
2018-05-10 |
2024-04-15 |
コンプリメント・セラピューティクス・リミテッド |
黄斑変性症を評価するための方法
|
JP7512207B2
(ja)
|
2018-05-24 |
2024-07-08 |
サーナオミクス インコーポレイテッド |
核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
|
EP3807291A4
(en)
*
|
2018-06-14 |
2022-02-23 |
University of Utah Research Foundation |
STAUFEN1 REGULATING AGENTS AND RELATED METHODS
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
EP4043015A1
(en)
|
2018-09-04 |
2022-08-17 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Delta-tocotrienol for treating cancer
|
US20210317479A1
(en)
|
2018-09-06 |
2021-10-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
US20230021500A1
(en)
|
2018-10-29 |
2023-01-26 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
CA3128059A1
(en)
|
2019-02-12 |
2020-08-20 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of cyp27a1
|
BR112021018739A2
(pt)
|
2019-03-29 |
2022-05-03 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
|
MX2021012126A
(es)
|
2019-04-04 |
2022-01-06 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
|
US11814464B2
(en)
|
2019-04-29 |
2023-11-14 |
Yale University |
Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
|
MX2021013418A
(es)
|
2019-05-03 |
2021-12-10 |
Dicerna Pharmaceuticals Inc |
Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
JP2022538868A
(ja)
|
2019-06-26 |
2022-09-06 |
バイオーケストラ カンパニー, リミテッド |
ミセルナノ粒子及びその使用
|
JP2022547790A
(ja)
|
2019-08-09 |
2022-11-16 |
ユニバーシティー オブ マサチューセッツ |
Snpを標的とする化学修飾オリゴヌクレオチド
|
EP4021496A1
(en)
|
2019-08-30 |
2022-07-06 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
US20220378920A1
(en)
|
2019-09-10 |
2022-12-01 |
Daiichi Sankyo Company, Limited |
CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
WO2021067744A1
(en)
|
2019-10-02 |
2021-04-08 |
Dicerna Pharmaceuticals, Inc. |
Chemical modifications of small interfering rna with minimal fluorine content
|
US11017851B1
(en)
|
2019-11-26 |
2021-05-25 |
Cypress Semiconductor Corporation |
Silicon-oxide-nitride-oxide-silicon based multi level non-volatile memory device and methods of operation thereof
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
TW202137987A
(zh)
|
2019-12-24 |
2021-10-16 |
瑞士商赫孚孟拉羅股份公司 |
用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
|
WO2021146487A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
WO2021150300A1
(en)
|
2020-01-22 |
2021-07-29 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
US11642407B2
(en)
|
2020-02-28 |
2023-05-09 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
BR112022018667A2
(pt)
|
2020-03-18 |
2022-11-29 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para inibir a expressão de ang-ptl3
|
CA3172111A1
(en)
|
2020-03-19 |
2021-09-23 |
Barbora MALECOVA |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
JP2023527638A
(ja)
|
2020-03-27 |
2023-06-30 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
IL297442A
(en)
|
2020-04-22 |
2022-12-01 |
Iovance Biotherapeutics Inc |
Systems and methods for coordinating production of cells for patient-specific immunotherapy
|
WO2021255262A1
(en)
|
2020-06-19 |
2021-12-23 |
Sylentis Sau |
siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
|
AU2021293780A1
(en)
|
2020-06-19 |
2023-02-02 |
Yale University |
Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
|
US20220031633A1
(en)
|
2020-07-28 |
2022-02-03 |
Yale University |
Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
|
JP2023538284A
(ja)
|
2020-08-04 |
2023-09-07 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッド |
Plp1発現を阻害するための組成物及び方法
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
WO2022031433A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
IL300340A
(en)
|
2020-08-05 |
2023-04-01 |
Hoffmann La Roche |
Treatment with oligonucleotides in hepatitis B patients
|
KR20230043912A
(ko)
|
2020-08-05 |
2023-03-31 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
AU2021331785A1
(en)
|
2020-08-31 |
2023-03-30 |
Gennao Bio, Inc. |
Compositions and methods for delivery of nucleic acids to cells
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
EP4214515A1
(en)
|
2020-09-16 |
2023-07-26 |
Complement Therapeutics Limited |
Complementome assay
|
EP4251170A1
(en)
|
2020-11-25 |
2023-10-04 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
CN117295753A
(zh)
|
2020-12-04 |
2023-12-26 |
基那奥生物公司 |
用于将核酸递送到细胞的组合物和方法
|
EP4015634A1
(en)
|
2020-12-15 |
2022-06-22 |
Sylentis, S.A.U. |
Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
CN117202894A
(zh)
|
2021-03-31 |
2023-12-08 |
胭脂红治疗私人有限公司 |
负载至少两个不同核酸的细胞外囊泡
|
WO2022218941A2
(en)
|
2021-04-12 |
2022-10-20 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for inhibiting ketohexokinase (khk)
|
KR20230171431A
(ko)
|
2021-04-14 |
2023-12-20 |
다이서나 파마수이티컬, 인크. |
Pnpla3 발현을 조절하기 위한 조성물 및 방법
|
WO2022223515A2
(en)
|
2021-04-19 |
2022-10-27 |
Novo Nordisk A/S |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
MX2023013504A
(es)
|
2021-05-28 |
2024-02-23 |
Novo Nordisk As |
Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1).
|
CA3221923A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Short duplex dna as a novel gene silencing technology and use thereof
|
WO2022256351A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
BR112023026862A2
(pt)
|
2021-06-23 |
2024-03-05 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023027759A1
(en)
|
2021-08-25 |
2023-03-02 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting αlpha-1 antitrypsin expression
|
CN118043076A
(zh)
|
2021-09-21 |
2024-05-14 |
约翰霍普金斯大学 |
用于细胞内递送的小分子生物制剂的树枝状大分子缀合物
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for the treatment of HBV
|
WO2023092089A1
(en)
|
2021-11-19 |
2023-05-25 |
Kist (Korea Institute Of Science And Technology) |
Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
|
AU2022402155A1
(en)
|
2021-12-01 |
2024-05-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating apoc3 expression
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
WO2023159189A1
(en)
|
2022-02-18 |
2023-08-24 |
Yale University |
Branched poly(amine-co-ester) polymers for more efficient nucleic expression
|
GB202203627D0
(en)
|
2022-03-16 |
2022-04-27 |
Univ Manchester |
Agents for treating complement-related disorders
|
WO2023192872A1
(en)
|
2022-03-28 |
2023-10-05 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
GB202204884D0
(en)
|
2022-04-04 |
2022-05-18 |
Fondo Ricerca Medica S R I |
Sirna targeting kcna1
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
US20230374522A1
(en)
|
2022-04-15 |
2023-11-23 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating scap activity
|
AR129311A1
(es)
|
2022-05-12 |
2024-08-14 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión de mapt
|
US20230416743A1
(en)
|
2022-05-13 |
2023-12-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting snca expression
|
US12064479B2
(en)
|
2022-05-25 |
2024-08-20 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
TW202400193A
(zh)
|
2022-06-24 |
2024-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024107993A1
(en)
|
2022-11-16 |
2024-05-23 |
Dicerna Pharmaceuticals, Inc. |
Stat3 targeting oligonucleotides and uses thereof
|
WO2024108217A1
(en)
|
2022-11-18 |
2024-05-23 |
Genkardia Inc. |
Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
GB202219829D0
(en)
|
2022-12-29 |
2023-02-15 |
Ivy Farm Tech Limited |
Genetically manipulated cells
|
WO2024151877A2
(en)
|
2023-01-11 |
2024-07-18 |
Engage Biologics Inc. |
Non-viral expression systems and methods of use thereof
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|